Abstract 2022-RA-1607-ESGO

Conclusion We have demonstrated that performing IDS within four weeks after NACT may be associated with better survival outcomes.

2022-RA-1611-ESGO

CHECKPOINT INHIBITION IN OVARIAN CANCER WORKS – A CASE REPORT OF COMPLETE RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN A PLATINUM RESISTANT PRIMARY OVARIAN CANCER PATIENT WITH LYNCH SYNDROME

1Lukas Chinczewski, 2Felix Wilhelm Feldhaus, 3Wolfgang Daniel Schmitt, 4Elena Ioana Braicu, 4Eva Roser, 5Jalid Sehouli. 1Department of Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2Radiology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 3Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany; 4Gynecology, Charité – Universitätsmedizin Berlin, Berlin, Germany

10.1136/ijgc-2022-ESGO.756

Introduction/Background Lynch syndrome is a secondary cause for hereditary ovarian cancer after BRCA mutation. Germline mutations in the DNA-mismatch repair genes cause tumorigenesis and a high immunogenicity. Recent studies showed a promising use of immunotherapy in MMR deficient (MMRd) tumors. We present a case of a patient with LS associated OC and a complete response to pembrolizumab.

Methodology

Results A 44-year old patient was admitted to the hospital with lower abdominal pain. The patient’s history showed LS with a germline mutation in the MSH2-gene. Initial diagnostics showed a pelvic tumor mass and a highly elevated cancer antigen 125. After debulking surgery, histopathological findings showed a high grade serous OC with a mutation in the MSH2 and MSH6-genes. Only 5 weeks after operation with cytoreduction, however, PET-CT is better at predicting complete response to pembrolizumab. Adjuvant therapy with carboplatin and paclitaxel in a weekly course did not lead to sustainable response. An anti-PD-L1 antibody therapy with pembrolizumab was initiated. After only 2 courses of therapy the laboratory results and clinical status of the patient improved tremendously. Shortly after a complete response was detected and until today for 28 cycles immune checkpoint inhibition therapy is ongoing. The patient remains tumor free for 21 months now.

Conclusion Recent studies suggest a promising effect of checkpoint inhibition within MMRd tumors. OC on the other hand does not seem to show an overall good response to immunotherapy. The significance of germline compared to somatic mutations has not yet been investigated in prior studies sufficiently. To our knowledge, this is the first case with complete response to checkpoint inhibition in OC associated with LS. Comprehensive testing for germline mutations should be established. Regarding Lynch syndrome associated ovarian cancer, immune checkpoint inhibition is an efficient therapy in tumors nonresponsive to standard therapy.

2022-RA-1621-ESGO

ROLE OF PET-CT AND CECT IN CALCULATING PREOPERATIVE PCI IN PATIENTS WITH EPITHELIAL OVARIAN CANCER

1Monica Gutierrez Martinez, 2Felix Boris, 3Lidia Sancho, 4Andrés Alcazar, 1Luís Chiva, 2Daniel Vázquez, 1Teresa Castellanos. 1Clínica Universidad de Navarra, Madrid, Spain; 2Clinica Universidad de Navarra, Clínica Universidad de Navarra, Spain

10.1136/ijgc-2022-ESGO.757

Introduction/Background The objectives are to compare the efficacy between preoperative PET/CT and CeCT findings according with the surgical findings in patients that underwent surgery for epithelial ovarian cancer treatment and to evaluate the correlation between preoperative PCI calculated in both PET/CT an CeCT with surgery.

Methodology Retrospective unicentric observational study reviewing data of 30 patients diagnosed with epithelial ovarian cancer (primary or recurrence) and operated between July 2018-February 2021 in Clínica Universidad de Navarra. Every patient underwent PET/CT and CeCT. PET/CT was independently evaluated by a nuclear medicine doctor (PET-CT) and CeCT by an expert radiologist in gynecologic malignancies. PCI in surgery was calculated by two different gynecologic oncologists. If there was any discordance between them, a media between both scores was applied. Medical history and demographic data, preoperative FIGO stage, PET/CT findings, CT findings final pathology diagnosis, type of surgery and perioperative details were reviewed. Intraclass correlation coefficient was calculated to compare the PCI obtained preoperatively in PET/CT and CeCT to the PCI obtained in the final surgery.

Results The interclass correlation coefficient in the global cohort of patients compared to the PCI calculated intraoperatively was 0.867 for CeCT and 0.807 for PET-CT. Regarding the prediction of complete cytoreduction, the area under the curve in the CeCT was 0.659 and 0.690 in the PET-CT.

Conclusion Despite the small sample size, this initial study highlights that CeCT is more effective in calculating PCI preoperatively, however, PET-CT is better at predicting complete cytoreduction. Further validation in larger series is needed.

2022-RA-1622-ESGO

MALIGNANT BRENNER TUMOR OF THE OVARY: CASE SERIES OF ONE SINGLE INSTITUTE

1Amani Jellali, 2Malek Bouhari, 3Takoua Chalouati, 4Saïda Sakhr, 5Ines Houissa, 2Ghada Sahraoui, 1Riadh Chargui, 1Khaled Rahal. 1Department of surgical oncology, Salah Azaiez Institute, Tunisia, Tunisia; 2Pathology department, Salah Azaiez Institute, Tunis, Tunisia

10.1136/ijgc-2022-ESGO.758
Introduction/Background Malignant Brenner tumors (MBT) of the ovary are rare disease; representing 1. 5% of all ovarian cancers and 3. 5% of Brenner tumors. They carry a poor prognosis. They generally affect women during the perimenopausal and postmenopausal periods. The aim of this study is to report our experience in the treatment of MBT of the ovary, to better characterize this disease.

Methodology A retrospective case series involving 5 patients diagnosed with MBT of the ovary and treated between 2006 and 2020.

Results The mean age of our patients was 54. 1 years. Four patients were in the menopause period. The tumor was staged as IC in one case, IIC in one case and IIIIC in three cases of FIGO classification. All women conducted surgery followed by adjuvant chemotherapy. Four patients underwent a loco-regional recurrence that occurred respectively after 9, 11 and 13 months in three patients. The treatment was based on chemotherapy, combined with surgery in one case. Two patients presented distant metastasis. The treatment consisted of chemotherapy and surgery. One patient of them died after surgery from massive pulmonary embolism. The mean follow up period was 39. 5 months.

Conclusion The treatment approach of MBT of the ovary is not well established since its scarcity and poor prognosis. Thus, more case series and meta-analysis should be conducted.